Emodin reduces tumor burden by diminishing M2-like macrophages in colorectal cancer
Alexander T. Sougiannis, Brandon N. VanderVeen, Ioulia Chatzistamou, Jason L. Kubinak, Mitzi Nagarkatti, Daping Fan, E. Angela Murphy
2022American Journal of Physiology-Gastrointestinal and Liver Physiology26 citationsDOIOpen Access PDF
Abstract
Our study confirms that emodin is an effective primary therapy against the onset of genetic and chemically induced sporadic colorectal cancer. We established that emodin reduces the M2-like protumorigenic macrophages in the tumor microenvironment. Furthermore, we provide evidence that emodin may be acting to antagonize the P2X7 receptor within the bone tissue and consequently decrease the activation of proinflammatory cells, which may have implications for recruitment of cells to the tumor microenvironment.
Topics & Concepts
EmodinColorectal cancerTumor microenvironmentProinflammatory cytokineCancer researchReceptorCancerChemistryMedicineImmunologyTumor cellsInternal medicineInflammationBiochemistryImmune cells in cancerImmune Cell Function and InteractionReproductive System and Pregnancy